Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

NCT07192432 ↗

Phase 1/2 Recruiting 27 enrolled Vironexis Biotherapeutics Inc.

NaSequentialOpen-labelTreatment

Summary

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.

Timeline

Start: 2025-11-18
Primary completion: 2033-09
Completion: 2033-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VNX-202	Gene therapy (AAV / viral vector)	—	Intravenous

Indications

No indication recorded.